Get the Stockscreener App
16.06
21.66%
3.44
Bioage Labs Inc stock is traded at $16.06, with a volume of 1.16M.
It is up +21.66% in the last 24 hours and up +32.24% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$12.62
Open:
$12.7
24h Volume:
1.16M
Relative Volume:
2.70
Market Cap:
$575.47M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.65%
1M Performance:
+32.24%
6M Performance:
+258.73%
1Y Performance:
+184.85%
1-Day Range:
$12.31
$16.14
1-Week Range:
$11.87
$15.40
52-Week Range:
$2.88
$15.40
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.05 | 452.49M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
129.56 | 57.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.79 | 49.57B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.25 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.09 | 35.57B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
503.35 | 21.08B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Can BioAge Labs Inc. stock deliver sustainable ROEQuarterly Earnings Review & Maximum Profit Growth - bollywoodhelpline.com
BioAge Labs upgraded to equal weight from underweight at Morgan Stanley - MSN
BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile
BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat
Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets
BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com
BioAge Labs announces positive phase 1 trial results - MSN
BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Catalysts & Real-Time Volume Trigger Notifications - Улправда
Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber
What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber
How analysts rate BioAge Labs Inc. stock today2025 Volume Leaders & High Accuracy Investment Signals - DonanımHaber
Bioage Labs Earnings Notes - Trefis
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
Bioage Labs Stock Rockets 52% With 8-Day Winning Streak - Trefis
Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells 18,000 Shares - TradingView — Track All Markets
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
Officer Rubin Files To Sell 18,000 Of BioAge Labs Inc [BIOA] - TradingView — Track All Markets
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
BioAge Labs Announces Positive Phase 1 Trial Results - The Globe and Mail
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Dec 09 '25 |
Option Exercise |
6.57 |
18,000 |
118,260 |
18,000 |
| RUBIN PAUL D | Chief Medical Officer |
Dec 09 '25 |
Sale |
12.00 |
18,000 |
216,000 |
0 |
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):